Natera Stock Hits Record High on New Colon Cancer Test Coverage

I was scrolling through my Bloomberg terminal last Thursday, coffee in hand, when a flash crossed the screen: Natera, Inc. (NTRA) up 12% in pre-market trading. My first thought — another biotech pop on vague trial data? But this was different. This was real. The company had just announced that its blood-based colon cancer screening test, Signatera, would now be covered by Medicare for certain high-risk patients. And the market, as it often does, reacted with a collective gasp of relief and excitement.

Shares of Natera hit an all-time high of $178.50 on Wednesday, closing at $176.20 — a gain of nearly 14% on the week. The catalyst? The Centers for Medicare & Medicaid Services (CMS) issued a final local coverage determination expanding reimbursement for Signatera to include colorectal cancer surveillance in patients with stage II or stage III disease who have completed curative-intent treatment. That’s a big deal. Not just for Natera, but for the roughly 150,000 Americans diagnosed with colorectal cancer each year.

What Is Signatera, and Why Should You Care?

Signatera is what’s called a circulating tumor DNA (ctDNA) test. Think of it as a molecular bloodhound. After a patient’s tumor is surgically removed, the test analyzes the tumor’s unique genetic fingerprint — its mutations — and then monitors the patient’s blood for any trace of that same DNA. If it shows up, it means cancer cells are lurking somewhere in the body, often months before a CT scan would catch them.

This isn’t just a fancy lab trick. It’s a paradigm shift in how we think about cancer recurrence. Traditionally, after surgery and chemotherapy, patients go into a watch-and-wait mode. They get scans every few months, hold their breath, and hope. But scans miss microscopic disease. Signatera can detect one mutant DNA molecule among 100,000 normal ones. That’s like finding a single grain of sand on a beach. And now, Medicare will pay for it — at least for colon cancer patients.

The decision from CMS covers about 40,000 to 50,000 Medicare beneficiaries annually, according to Natera’s estimates. At a list price of roughly $2,500 per test, and with patients typically getting tested every three to six months for up to three years, the revenue potential is enormous. Analysts at Jefferies projected that this coverage decision alone could add $300 million to $500 million in annual revenue for Natera by 2027.

The Stock Market’s Love Affair with Liquid Biopsy

Natera isn’t the only player in the liquid biopsy space. Guardant Health, Exact Sciences, and Grail are all jostling for position. But Natera has carved out a niche by focusing on minimal residual disease (MRD) testing — that is, detecting cancer after treatment — rather than just screening for new cancers. And the market is rewarding that focus.

“This is a watershed moment for MRD testing in colorectal cancer,” said Dr. Sarah Thompson, an oncologist at the University of Texas MD Anderson Cancer Center. “We’ve had the data for a while showing that ctDNA positivity predicts recurrence with high accuracy. But without reimbursement, it was hard to justify using it routinely. Now, Medicare has essentially validated the clinical utility. Private insurers will likely follow.”

And follow they have. Within 48 hours of the CMS announcement, Anthem and UnitedHealthcare both issued draft policies expanding coverage for Signatera in colorectal cancer. The dominoes are falling. Natera’s stock, which had already doubled over the past 12 months, now trades at a forward price-to-sales ratio of 8.5 — not cheap, but not insane for a company growing revenue at 30% annually.

But here’s the thing: Natera’s success isn’t just about colon cancer. The company is also developing Signatera for breast, lung, and bladder cancers. If the same reimbursement pattern holds — and there’s reason to think it will — the addressable market expands from hundreds of thousands to millions of patients. That’s the kind of story that gets growth investors salivating.

The Broader Context: Why This Matters for Your Portfolio

Let’s zoom out for a second. The healthcare sector has been a mixed bag in 2025. The S&P 500 Health Care Index is up about 8% year-to-date, lagging the broader market’s 12% gain. Drug pricing reform, regulatory uncertainty, and the GLP-1 craze have diverted attention. But precision oncology — and liquid biopsy in particular — is quietly becoming one of the most compelling sub-sectors.

Consider this: The global liquid biopsy market was valued at $6.5 billion in 2024 and is projected to hit $18.2 billion by 2032, according to Grand View Research. That’s a compound annual growth rate of 13.8%. Natera, with its first-mover advantage in MRD and now a clear reimbursement pathway, is positioned to capture a disproportionate share of that growth.

Of course, there are risks. Competition is fierce. Guardant Health’s Guardant Reveal test is already approved for colorectal cancer surveillance, and Exact Sciences’ Cologuard is the dominant stool-based screening test. But Natera’s technology is different — it’s tumor-informed, meaning it’s personalized to each patient’s cancer, rather than a one-size-fits-all panel. That specificity could give it an edge in accuracy, especially for detecting recurrence.

And then there’s the valuation question. Natera isn’t profitable yet. It lost $420 million in 2024 on revenue of $1.2 billion. But the company expects to reach operating breakeven by late 2026, driven by this new coverage and expanding test volumes. For growth investors, that’s a familiar story — lose money now, make it up later. For value investors, it’s a hard pass. But the market is clearly betting on the latter scenario.

Interestingly, the rally in Natera also lifted other liquid biopsy stocks. Guardant Health rose 5% on the week, and Exact Sciences gained 3%. It’s a reminder that in biotech, a rising tide lifts all boats — at least temporarily. But Natera is the clear leader in this wave.

For a different take on market momentum, check out our analysis of Figma (FIG): The Best Stock to Buy Right Now (Not SpaceX), where we break down why software companies are also seeing explosive growth. And if you’re interested in how regulatory shifts can reshape entire industries, our piece on Comcast Stock Soars on Split – But the Real Story Is Bigger offers a parallel lesson in corporate strategy.

What This Means for Patients — and the Future of Cancer Care

Let’s not lose sight of the human element here. Colon cancer is the second leading cause of cancer death in the United States. When it recurs after treatment, it’s often aggressive and hard to treat. Catching it early — even just a few months earlier — can mean the difference between curative surgery and palliative chemo.

“I’ve had patients who were told they were ‘cancer-free’ based on scans, only to have Signatera detect recurrence three months later,” said Dr. Michael Chen, a colorectal surgeon at the Mayo Clinic. “That early warning allowed us to intervene with immunotherapy while the tumor burden was still low. Some of those patients are now in long-term remission. This test changes the calculus.”

Medicare’s decision doesn’t just affect seniors. Private insurers often follow Medicare’s lead. So within a year or two, most commercially insured patients with stage II or III colon cancer will likely have access to Signatera without prior authorization headaches. That’s a win for patients, for doctors, and for Natera’s bottom line.

But the bigger story is what this means for the future of cancer surveillance. If ctDNA testing becomes standard of care for colon cancer, it’s only a matter of time before it’s adopted for other solid tumors. Natera is already running clinical trials for pancreatic, ovarian, and gastric cancers. The data so far is promising. And if reimbursement follows, the company could become the go-to platform for post-treatment monitoring across multiple cancer types.

That’s a long-term thesis that goes beyond a single stock pop. It’s a bet on the digitization of oncology — using molecular data to guide treatment decisions in real time. And it’s a bet that, so far, is paying off.

So where does Natera go from here? The stock is at an all-time high, and momentum is strong. But biotech is notoriously volatile. A single negative trial result or a competitor’s breakthrough could send shares tumbling. For now, though, the wind is at Natera’s back. The CMS decision has opened a door that won’t close anytime soon. And for investors willing to stomach the volatility, the potential reward is substantial.

As always, do your own due diligence. But if you’re looking for a growth story with real-world impact — and a stock that’s riding a regulatory tailwind — Natera deserves a spot on your watchlist.